Modulation of T-Cell Ontogeny by Transplacental Benzo(a)pyrene
-
1995/04/01
-
Details
-
Personal Author:
-
Description:Transplacental exposure to the carcinogen, benzo(a)pyrene BaP, leads to depressed immune function and increased tumor incidence in mice. This paper reports ontogenetic T-cell changes in BALB/c mice after exposure to BaP in utero. Monoclonal antibodies (MAbs) were produced to fetal liver T-cells (FLT) and newborn spleen (NBS) lymphocytes purified from offspring of pregnant BALB/c mice that were given one injection of BaP (150 mg/kg body weight) in mid-gestation (day 11-13). The MAbs reacted with two T-cell membrane antigens (FLT and NBS) found in fetal liver, neonataI and adult thymus and spleen. Lymphocytes of BaP-exposed 19-day fetuses showed decreased subpopulation frequencies (P<0.05) in fetal liver total T-ceIls (from 56% to 16%), Lyl cells (from 33% to 9%), and Ly2 cells (from 56% to 1%) compared with untreated controls. In contrast, BaP increased the subpopulation frequencies (P<0.05) in FLT cells in fetal liver (from 20% to 52%) and in newborn spleen (from 21% to 51%), and increased NBS cells in newborn spleen (from 24% to 59%). The increased frequency in FLT and NBS cells was due to their relative resistance to BaP toxicity and/or BaP-enhanced proliferation in the neonatal period. Compared with untreated controls, BaP treatment resulted in reduced numbers of T-cells in fetal liver and showed a selective toxicity for Lyl cells (89% reduction) and Ly2 cells (99% reduction), whereas FLT cells were not reduced and NBS cells were reduced by 60%. Six-week-old juvenile mice exposed to BaP in utero showed recovery of total T-cells to control levels in spleen and thymus, but showed depletion (P<0.01) in thymic FLT cells (from 81% to 12%) and in splenic NBS cells (from 55% to 16%). The monoclonal antibodies developed for this study recognize novel cellular changes in the murine immune system that are associated with transplacental BaP. The FLT and NBS antigens may be useful biomarkers for developmental immune dysfunctions in progeny exposed to BaP in utero. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:0192-0561
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Pages in Document:339-350
-
Volume:17
-
Issue:4
-
NIOSHTIC Number:nn:20035622
-
Citation:Int J Immunopharmacol 1995 Apr; 17(4):339-350
-
Contact Point Address:ZL Lummus, University of Cincinnati Medical Center, Department of Internal Medicine, Division of Immunology, ML 563, 231 Bethesda Avenue, Cincinnati, OH 45267-0563
-
Federal Fiscal Year:1995
-
Performing Organization:University of Cincinnati, Cincinnati, OH
-
Peer Reviewed:True
-
Start Date:19990930
-
Source Full Name:International Journal of Immunopharmacology
-
End Date:20030929
-
Collection(s):
-
Main Document Checksum:urn:sha-512:73ae16e874b0227b861c4bebe3ca413b3886012a60bff9f0e6fe9c3a2e02e1f62c77b59830f3886531450469e9a3a9ee13b7c72a762186c1a3d76bd4f78c1cee
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like